RECURSION PHARMACEUTICALS, INC. (RXRX)

Every figure this model derived for RXRX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,789,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 545,683,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 603,462,000 AssetsCurrent 2026-06-30
current liabilities 119,886,000 LiabilitiesCurrent 2026-06-30
equity 915,003,000 StockholdersEquity 2026-06-30
interest expense 1,481,000 InterestExpenseNonoperating 2026-06-30
ocf -350,481,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 54,855,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 90,719,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up RXRX on one particular measure came for.

RatioValue
cash operating margin-683.49
current ratio6.54
current ratio reported5.03
deferred revenue growth-30.5
dilution pct63.23
fcf margin-642.18
growth cv1.03
interest cover-367.33
operating margin-991.72
owner earnings margin-807.56
revenue growth-15.08
revenue growth per share-47.98
roic-112.06
rule of 40-1006.8
sbc pct revenue165.38

What to be careful about

What this model itself distrusts about RXRX's figures. Written by the derivation as it ran, not added afterwards.